Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunfa Cheng

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Headache|October 16, 2019
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese AdultsFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.
Headache|June 21, 2021
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled studyTakao Takeshima, Fumihiko Sakai, Koichi Hirata, et al.
Cephalalgia : an International Journal of Headache|May 13, 2021
Efficacy of erenumab in chronic migraine patients with and without ictal allodyniaRichard B Lipton, Rami Burstein, Dawn C Buse, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 16, 2006
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunBMaria Alejandra Alfonso-Jaume, Marina R Bergman, Rajeev Mahimkar, et al.
Kidney Medicine|May 31, 2022
Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World EffectivenessAngelo Karaboyas, Daniel Muenz, Yunji Hwang, et al.
The Journal of Headache and Pain|September 19, 2021
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trialKoichi Hirata, Fumihiko Sakai, Takao Takeshima, et al.
BMJ Open|August 19, 2023
Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trialKoichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|July 10, 2018
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyMessoud Ashina, Stewart Tepper, Jan Lewis Brandes, et al.
Cephalalgia : an International Journal of Headache|March 29, 2020
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension studyStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Headache|October 16, 2019
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese AdultsFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.
Headache|June 21, 2021
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled studyTakao Takeshima, Fumihiko Sakai, Koichi Hirata, et al.
Cephalalgia : an International Journal of Headache|May 13, 2021
Efficacy of erenumab in chronic migraine patients with and without ictal allodyniaRichard B Lipton, Rami Burstein, Dawn C Buse, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 16, 2006
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunBMaria Alejandra Alfonso-Jaume, Marina R Bergman, Rajeev Mahimkar, et al.
Kidney Medicine|May 31, 2022
Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World EffectivenessAngelo Karaboyas, Daniel Muenz, Yunji Hwang, et al.
The Journal of Headache and Pain|September 19, 2021
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trialKoichi Hirata, Fumihiko Sakai, Takao Takeshima, et al.
BMJ Open|August 19, 2023
Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trialKoichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|July 10, 2018
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyMessoud Ashina, Stewart Tepper, Jan Lewis Brandes, et al.
Cephalalgia : an International Journal of Headache|March 29, 2020
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension studyStewart J Tepper, Messoud Ashina, Uwe Reuter, et al.
Pageof 5